1
Introduction 15
Tumor suppressor p53 is a transcription factor that acts as a sensor of multiple stress stimuli, 16 e.g. DNA damage, hypoxia and oncogenic stress. Depending on the type and severity of the 17 stress and other factors, p53 triggers distinct cellular responses including cell cycle arrest, 18 senescence and apoptosis 1, 2 . More recent studies have shown that p53 also has roles in 19 metabolism 3 , stem cell division 4 , fertility 5 and cell death by ferroptosis 6 . The TP53 gene is 20 inactivated by mutation in a large fraction of human tumors 7, 8 . The majority of TP53 21 mutations are missense mutations resulting in substitution of amino acid residues that make 22 direct contact with DNA, such as R248W and R273H, or residues that are important for the 23 structural integrity of the core domain, e.g. R175H and R249S. This leads to loss of specific 24 DNA binding 9 . 25 1 The high frequency of TP53 mutations in human tumors has stimulated efforts to develop 2 therapeutic strategies for targeting mutant p53 in cancer. Several low-molecular-weight 3 compounds have been reported to restore wild-type function to mutant p53 including PRIMA-4 1 and the PRIMA-1 analog APR-246 (PRIMA-1 Met ) 10, 11, 12, 13, 14, 15, 16, 17 . APR-246 has been 5 tested in a phase I/IIa clinical trial in patients with hematological malignancies or prostate 6 cancer 18 . APR-246 is converted in vitro and in vivo to methylene quinuclidinone (MQ), a 7
Michael acceptor that reacts with thiols in cysteines in the p53 core domain 19 . However, the 8 mechanism by which APR-246/MQ reactivates mutant p53 is not fully understood. 9 10 Many mutant p53 proteins in human tumors are thermodynamically unstable at body 11 temperature 20 . Studies of temperature-sensitive mutants suggest that stabilization of 12 conformation is critical for regaining wild-type p53 activity 21, 22 . Thus, pharmacological 13 stabilization of mutant p53 should allow its functional rescue and efficient elimination of 14 tumor cells 23 . 15 16 Here we have examined the role of the Michael acceptor activity of MQ for 17 thermostabilization of wild-type (wt) and mutant p53 core domains and refolding of R175H 18 mutant p53 in living cells. We also show that Cys277 is essential for MQ-mediated 19 thermostabilization of R175H and R273H mutant p53 core domains, and that both Cys124 20 and Cys277 are required for APR-246-mediated R175H mutant p53 reactivation in tumor 21 cells. 22 23 24 25
Results 1
MQ binds to the p53 core domain via Michael addition 2
We have previously shown that conversion products of PRIMA-1 covalently bind to cysteine 3 residues in the p53 core domain and reactivate mutant p53 (ref. 19) , but whether MQ, the 4 active conversion product of APR-246, itself binds to the p53 core domain has not been 5 unequivocally demonstrated. To address this, we analyzed MQ-treated p53 core domains by 6 Nanomate Linear Ion Trap Orbitrap (LTQ) hybrid mass spectrometry. Accurate masses of the 7 wt and R273H and R175H mutant p53 core domains are shown in Figure 1a . We incubated wt 8 and R273H mutant p53 core domains (20µM) with 50µM, 100µM or 200µM MQ at 21°C and 9 assessed the degree of thiol modification by LTQ-MS. The deconvoluted mass spectra 10 showed that 32% of the wt and R273H p53 core domain proteins were modified by one MQ 11 molecule when incubated with lower concentrations of the compound (Figure 1b ), and that all 12 wt and R273H p53 protein molecules had two MQ adducts upon incubation with 200µM MQ 13 ( Figure 1d ). We did not detect modification of all 10 cysteines in p53 core at this range of 14 MQ concentrations. 15
16
Since we only obtained a low yield of the R175H p53 core domain, we analyzed it at lower 17 protein concentration than wt and R273H (see Methods). Briefly, R175H core domain (3.2µM) 18 was incubated with 10µM, 25µM or 50µM MQ. The deconvoluted mass spectra indicate that 19 20% of the R175H core was modified by one MQ molecule at 10µM (Figure 1c ), and at 20 50µM MQ, 35% of the R175H core domain protein had one MQ adduct and 14% had two 21 MQ adducts ( Figure 1d ). Thus, the number of p53 cysteine residues modified by MQ 22 increased in a dose-dependent manner. 23 24 Next, we assessed binding of MQ-H, a hydrogenated analog of MQ that lacks the reactive 1 carbon-carbon double bond ( Figure 1e ). We did not detect any modification at concentrations 2 up to 200µM, indicating that MQ-H does not modify cysteine residues in p53. Thus, the 3 Michael acceptor activity of MQ is required for modification of cysteines in p53. 4
5

MQ enhances thermostability of the p53 core domain 6
To address the question if the modification of cysteine residues in p53 by MQ increases the 7 thermostability of the p53 core domain, we applied differential scanning fluorimetry (DSF). 8
This method allows analysis of the interactions between a protein and a ligand based on 9 changes in the melting temperature of the protein (Tm). DSF demonstrated that the wt p53 10 core domain was the most stable of the three proteins with a Tm of 40.38±0.06ºC. Tm for the 11 DNA contact mutant R273H was 39.16±0.52ºC, whereas the structural mutant R175H was the 12 least stable protein with a Tm of 30.64±0.46ºC (Figure 2a ). This is in a good accordance with 13 previously published studies 20 . To further validate this result, we used circular dichroism 14 (CD), which allows assessment of α-helix and β-sheet structures content. We performed CD 15 analysis at 218 nm since both α-helix and β-sheet structures are detected at this wavelength. 16
In agreement with our DSF data, CD measurements demonstrated that wt p53 core domain is 17 the most stable protein followed by R273H core whereas the R175H core domain is 18 considerably less stable. The Tm values are 44.74±0.08ºC, 43.96±0.37ºC and 36.24±0.33°C, 19 respectively. 20
21
We then incubated wt, R273H and R175H p53 core domains with 2mM MQ followed by DSF 22 and CD analyses. This concentration of MQ was chosen to override the reducing agents DTT 23 or TCEP that are included in the reaction buffer to maintain wild-type-like structure of the 24 p53 core domains in solution. According to DSF, MQ increased the Tm values of wt, R273H 25 and R175H p53 core domains by 3.44ºC, 3.54ºC and 2.31ºC, respectively (Figure 2a ). This 1 degree of p53 core domain thermal stabilization upon binding of a small molecule is in 2 agreement with previously published results 16 . CD analysis confirmed thermostabilization of 3 all three core domains by MQ as shown by the increase in Tm values by 1.20°C, 1.70°C and 4 2.06ºC for wt, R273H and R175H p53, respectively (Figure 2b ). The inactive MQ analog, 5 MQ-H did not significantly change the thermal stability of the p53 core domains as assessed 6 by DSF ( Figure 2a ) and CD ( Figure 2b) . 7 8 Thus, MQ but not MQ-H increases the thermostability of the p53 core domain proteins, 9 confirming that cysteine binding by Michael addition is critical for p53 thermostabilization by 10 MQ. The results from DSF and CD were fully consistent; the p53 protein melting 11 temperatures determined by the two methods correlated with each other (r=0.999, p=0.007). 12 DSF was chosen for further studies. 13 14
Identification of MQ binding sites in the p53 core domain 15
The p53 core domain has 10 cysteine residues with varying solvent accessibility. Previous 16 studies have indicated that in the absence of DNA Cys277 has the highest solvent 17 accessibility, followed by Cys182 and Cys229, whereas Cys135, Cys141 and Cys275 have 18 poor solvent accessibility 24 . Cys124 is located at the center of the flexible L1/S3 pocket, 19 which can be stabilized by second-site mutations to rescue mutant p53 folding 25, 26, 27 . 20
Interestingly, Cys124 shows a nuclear magnetic resonance (NMR) chemical shift upon 21 binding of the CDB3 peptide that stabilizes mutant p53 (ref. 28). In addition, mutation at 22
Cys124 was reported to abrogate reactivation of R175H mutant p53 by . 23 24 Thus, to investigate if the most solvent-exposed cysteine residues and Cys124 are critical for 1 MQ binding to the p53 core, we first introduced single Cys to Ala substitutions at position 2 124, 182, 229 or 277 in the wt, R175H and R273H p53 core domains, and double 3 substitutions at Cys124 and Cys277 in the same three core domain proteins. The R175H p53 4 core domain has low intrinsic thermostability and additional amino acid substitutions might 5 destabilize it further. This probably explains why we only obtained negligible protein yield 6 for the R175H-C124A and R175H-C124A-C277A core domains. Our LTQ-MS analysis of 7 R273H mutant p53 core domains identified one MQ adduct in the R273H, R273H-C124A, 8 R273H-C182A, and R273H-C229A p53 cores after incubation with 50µM MQ, whereas no 9 MQ modification of the R273H-C277A and R273H-C124A-C277A core domains was 10 detected ( Figure 3a ). However, incubation with 100-200µM MQ resulted in two to five MQ 11 adducts in all p53 mutant core domains tested except R273H-C277A (Figure 3 b-c). This 12 implies that MQ modifies several cysteines in p53, and suggests that Cys277 is the most 13 reactive. 14
15
Cys277 is essential for MQ-mediated thermostabilization of p53 core domains 16
In order to assess the role of selected Cys residues in MQ-mediated thermostabilization, we 17 incubated wt, R175H and R273H p53 core domains carrying indicated Cys to Ala 18 substitutions with MQ and performed DSF. The Tm values of the wt and p53 core domains 19 carrying C124A, C277A, C182A, C229A and C124A-C277A substitutions were 42.36°C, 20 36.67°C, 43.07°C, 42.43°C, 40.59°C and 40.91°C, respectively (Table 1 ). MQ modification 21 increased the Tm values of the C124A, C182A and C229A p53 core domain proteins by 22 5.82°C, 1.35°C and 1.00°C (Figure 4a ), respectively. In contrast, MQ caused a slight 23 destabilization of the C277A core domain by -0.06°C, and only stabilized the C124A-C277A 24 core domain by 0.16°C, indicating that Cys277 is critical for MQ-mediated 1 thermostabilization of p53. 2 3 We then analyzed R273H p53 cores with the same C124A, C277A, C182A and C229A 4 substitutions. The melting temperatures of the R273H, R273H-C124A, R273H-C227A, 5 R273H-C182A and R273H-C229A p53 core domains were 40. 49°C, 39.17°C, 41.48°C, 6 40.52°C and 38.60°C, respectively (Table 1) . MQ treatment shifted the Tm values by 0.93°C, 7 0.64°C, -0.19°C, 1.03°C and 0.76°C (Figure 4b ), respectively. The Tm of the R273H core 8 domain with C124A-C277A double substitution was 39.48°C and only changed by -0.07°C 9 upon MQ modification. 10
11
As indicated above, we were not able to obtain sufficient amounts of the R175H-C124A and 12 R175H-C124A-C277A p53 core domains. Thus, only the R175H, R175H-C277A, R175H-13 C182A and R175H-C229A core domains were further analyzed. Their respective melting 14 temperatures were 31.09°C, 29.05°C, 29.49°C and 28.16°C (Table 1) . MQ modification 15 shifted the melting temperatures by 0.71°C, -0.12°C, 0.73°C and 0.45°C (Figure 4c ), 16 respectively. Thus, C227A substitution abrogated MQ-induced thermostabilization in wt as 17 well as R273H and R175H mutant p53 core domain backgrounds. 18
19
Our MS data demonstrate that MQ binds to the p53 core domain in a concentration-dependent 20 manner and that high concentrations of MQ lead to modification of more than one cysteine 21 residue in p53. This raises the question whether high concentrations of MQ might induce p53 22 thermostabilization even in the absence of Cys277. To address this, we incubated wt, C277A, 23 C124A-C277A, R175H-C277A and R273H-C277A p53 core domains with 1 mM, 2 mM or 4 24 mM MQ and assessed protein thermostability by DSF ( Figure 4d ). The highest concentration 25 of MQ (4 mM) destabilized all core domains ( Figure 4d ). The wt p53 core domain was 1 stabilized by MQ at 1 and 2 mM, as observed previously. However, p53 core domains with 2 the C277A substitution were not stabilized at the same concentrations. Thus, this result 3 further supports our conclusion that Cys277 is indispensable for MQ-mediated p53 core 4 domain stabilization. 5 6 APR-246 and MQ induce R175H mutant p53 refolding to wild-type conformation 7
Proper folding of p53 is crucial for sequence-specific DNA binding and transactivation of p53 8 target genes. As a rule, TP53 mutations in tumors lead to p53 unfolding and loss of sequence-9 specific DNA binding capacity. PRIMA-1 was shown to promote R175H mutant p53 10 refolding to wild-type conformation in SKOV-His175 cells 11 . However, this has yet to be 11 demonstrated for APR-246 and MQ. 12
13
The wild-type p53 conformation-specific monoclonal antibody PAb1620 allows detection of 14 mutant p53 refolding to wild-type-like conformation. We verified specificity of the PAb1620 15 antibody in immunostaining by treating HCT116 human colon carcinoma cells with 16 doxorubicin to induce the levels of wild-type p53. HCT116 cells expressing wild-type p53 or 17 Saos-2 cells expressing R273H mutant p53, which retains wild-type-like conformation, 18 showed PAb1620+ staining ( Supplementary Figure 1) . In contrast, H1299 cells expressing 19 R175H mutant p53 were PAb1620 negative. Treatment with APR-246 induced positive 20 PAb1620 staining in H1299-R175H cells, suggesting that APR-246 via MQ restores wild-21 type conformation of this mutant ( Supplementary Figure 1) . 22
23
To determine if APR-246 and MQ can refold endogenous R175H mutant p53 in TOV-112D 24 ovarian carcinoma cells, we treated the cells with APR-246 or MQ and performed co-25 immunostaining with PAb1620 and anti-p53 polyclonal antibody FL-393. In parallel, the cells 1 were stained with the monoclonal HO3.5 antibody that specifically detects unfolded p53 2 conformation in a manner similar to PAb240 (ref. 29) . APR-246 treatment increased 3 PAb1620 staining ( Figure 5a ) and decreased HO3.5 staining (Figure 5b ), indicating refolding 4 of R175H mutant p53 to wild-type-like conformation. 5 6 Next, we treated TOV-112D cells with MQ and stained with PAb1620 and HO3.5 antibodies. 7
Like APR-246, MQ induced PAb1620 staining (Figure 5a ), which coincided with decreased 8 HO3.5 staining (Figure 5b ). We did not detect any changes in PAb1620 and HO3.5 staining 9 after treatment with MQ-H, confirming that the Michael acceptor activity of MQ is crucial for 10 mutant p53 refolding in living tumor cells. To investigate the role of cysteine residues in mutant p53 reactivation by APR-246/MQ in 15 tumor cells, we transiently transfected p53 null H1299 cells with vectors encoding R175H, 16 R175H-C124A, R175H-C277A or R175H-C124A-C277A p53 mutant proteins, or with 17 control vector (pCMV). Western blotting confirmed similar levels of expression of p53 in all 18 transfectants ( Supplementary Figure 2) . Next, the cells were treated with 45µM APR-246. We 19 chose this concentration since it induced cell death in R175H mutant p53-transfected cells 20 but only marginally affected empty vector-transfected cells. We then assessed apoptosis and 21 expression of p53 targets p21, Fas and Bax by flow cytometry. Signals obtained in mock-22 treated control cells were subtracted from the corresponding signals obtained in APR-246-23 treated cells, and the values are presented as relative increase, namely ΔAnnexin V, Δp21, 24
ΔFas and ΔBax. Cells transfected with R175H showed substantial induction (by 61.06%) of 25 Annexin V staining after APR-246 treatment when compared to cells transfected with pCMV 1 empty vector (3.91%). We observed relatively low induction of Annexin V staining in cells 2 transfected with R175H-C124A p53 (13.96%), whereas cells expressing R175H-C277A or 3 R175H-C124A-C277A p53 showed no induction of Annexin V staining as compared to 4 control vector-transfected cells (Figure 6a ). The p53 targets p21 ( Figure 6b ) and Bax ( Figure  5 6c) were highly induced by APR-246 in cells expressing R175H p53 but only slightly or 6 moderately increased in cells expressing the R175H-C124A and R175H-C124A-C277A 7 mutants. Cells expressing R175H-C277A mutant p53 showed no induction of p21 or Bax. 8
The p53 target Fas ( Figure 6d TP53 gene mutation occurs in around 50% of human tumors and is emerging as predictive 2 biomarker for currently available cancer therapy. A number of in vitro, ex vivo and in silico 3 approaches have been applied to identify small molecules that reactivate mutant p53 by 4 restoring wild-type p53 conformation 10, 30 . The mutant p53-targeting compound APR-246 has 5 been tested in a phase I/IIa clinical trial in patients with hematological malignancies or 6 prostate cancer 18, 31 , and is currently being tested in a phase II clinical trial in patients with 7 high-grade serous (HGS) ovarian cancer (see clincaltrials.gov). Both PRIMA-1 and APR-246 8 are converted to methylene quinuclidinone (MQ) 19 . MQ is a potent electrophile that has a 9 highly reactive carbon-carbon double bond coupled to the electron-withdrawing carbonyl 10 group, defining it as a Michael acceptor. At physiological conditions, thiols in proteins are 11 good nucleophiles and therefore prime targets for electrophilic attack by MQ. Our earlier 12 studies clearly demonstrated thiol modifications in the p53 core domain by PRIMA-1 13 conversion products 19 . This led us to conclude that APR-246-mediated mutant p53 14 reactivation involves covalent binding of MQ to p53. Several other mutant p53-reactivating 15 compounds, such as MIRA-1 (ref. 32), CP-31398 and STIMA-1 (ref. 33), 3-benzoylacrylic 16 acid 14 and 2-sulfonylpyrimidines 16 , possess similar reactivity with thiols, indicating that the 17 observed association between thiol reactivity and mutant p53 reactivation is not coincidental. 18
19
A few methods have been successfully used to measure protein thiol modifications including 20 antibody-based detection or chemical tagging of the modified thiol groups 34 . However, the 21 development of mass spectrometry (MS) methods allowing the analysis of proteins using 22 electrospray ionization (ESI) coupled with high-resolution instrumentation has significantly 23 advanced studies of thiol modifications. Here we applied LTQ-MS to assess p53 core domain 24 thiol modifications. We show that the MQ analog MQ-H that lacks a reactive carbon-carbon 25 double bond and therefore lacks Michael acceptor activity, unlike MQ itself, does not modify 1 cysteine residues in the p53 core domain, does not enhance p53 thermostability and does not 2 induce R175H mutant p53 refolding according to PAb1620 staining. Thus, by using several 3 approaches, we demonstrate that the electrophilic properties of MQ are essential for cysteine 4 modification, thermostabilization and refolding of mutant p53. 5 6 Although previous studies have indicated that PRIMA-1 conversion products bind covalently 7 to the p53 core domain 19 , the exact cysteine target residues for the major PRIMA-1 and APR-8 246 conversion product MQ have remained unknown. We applied LTQ-MS analysis to a set 9 of Cys to Ala mutants to identify cysteine residues that are critical for MQ binding and MQ-10 mediated stabilization of mutant p53. The reactivity of cysteine residues in a protein is largely 11 affected by their solvent accessibility. Among 10 cysteines in p53 core domain, Cys176, 12
Cys238 and Cys242 coordinate a zinc ion which is responsible for holding p53 loops 13 together 9 , making them less likely targets for modification. Cys135, Cys141 and Cys275 are 14 poorly accessible to solvent based on the X-ray crystal structure of the p53 core domain. 15
Cys277 and Cys182 have the highest solvent accessibility, followed by Cys229 (ref. 24). 16 Interestingly, Cys277 has the lowest pKa of all p53 cysteines, making it the strongest 17 nucleophile in the protein. Thus, Cys 277 combines the greatest solvent accessibility with the 18 highest nucleophilicity, suggesting that it might be a prime target for MQ. 19 20 Indeed, we found that Cys277 to Ala substitution abolishes MQ binding to p53 core domain, 21 at lower concentrations. Moreover, the ability of MQ to thermostabilize p53 core domains is 22 impaired in Cys277 to Ala p53 mutants. Thus, a good correlation exists between the extent of 23 MQ adduct formation and MQ-mediated thermostabilization of the p53 core domain. 24 25 Cys182 and Cys277 have recently been identified as the prime binding sites for PK11000, a 1
2-sulfonylpyrimidine compound that reacts with cysteines and thermostabilizes p53 (ref. 16). 2
It is noteworthy that although Cys277 interacts directly with DNA, modification of this 3 residue by PK11000 did not change p53 DNA binding and transactivation of target genes. 4
Our results demonstrate that substitution of Cys182 to Ala does not affect p53 modification 5 and thermostabilization by MQ in any significant way, implying that Cys182 is not essential 6 for mutant p53 reactivation by APR-246/MQ. 7 8 Kaar and colleagues 14 identified 3-benzoylacrylic acid as a thiol-binding compound that reacts 9 first with Cys124 and Cys141 and to a lesser extent with Cys135, Cys182 and Cys277 in p53. 10
Cys124 was also identified as a target for PRIMA-1 by molecular modelling, and Cys124 to 11 Ala substitution abolished PRIMA-1-induced reactivation of mutant p53 in human tumor 12 cells 25 . Here, we examined the role of Cys124 and found that substitution of this cysteine did 13 not impair MQ binding and p53 thermostabilization. However, Cys124 to Ala substitution 14 abrogated R175H reactivation by APR-246/MQ in tumor cells, in agreement with the results 15 of Wassmann et al. 25 . 16 17 In order to exclude the possibility that the Cys to Ala substitutions themselves impair wild-18 type p53 function in our experimental setting, we examined whether the Cys to Ala 19 substitutions impair ability of p53 to transactivate p21 and induce apoptosis. We confirmed 20 that these substitutions do not affect normal p53 function to any major extent, supporting the 21 notion that the observed effects are indeed due to an important role of Cys124 and Cys277 for 22 APR-246/MQ-mediated mutant p53 reactivation. 23
24
In conclusion, our data demonstrate that specific cysteines are critical targets for mutant p53 1 reactivation by APR-246/MQ. Our findings may open opportunities for designing novel 2 compounds targeting mutant p53 based on a similar mechanism of nucleophilic addition at the 3 identified binding sites. 
Mass spectrometry 25
Wild-type and R273H p53 core domains were de-salted against 20 mM ammonium acetate 1 buffer by using 10K concentration columns (Vivaspin, GE Healthacare, Chicago, IL). 2 Twenty µM of the purified protein were incubated with 0 µM (control), 50 µM, 100µM or 3 200µM MQ for 15min at.21°C. R175H core domains were de-salted by ZipTip C4 resin tips 4 for MALDI-ToF MS (Merck Millipore, Billerica, MA) following the manufacturer protocol. 5 3.2µM of R175H protein were treated with 0µM (control), 10µM, 25µM or 50µM of MQ for 6 15min at 21°C. 5% formic acid (1:1 volume ratio) was added to the samples to increase the 7 ionization sensitivity. Samples were analyzed by LTQ XL mass spectrometry (Thermo Fisher  8 Scientific, Waltham, MA) fitted with an automated nanospray source (TriVersa Nanomate, 9
Advion Biosciences, Ithaca, NY) using nanoelectrospray chips with spraying nozzels. The ion 10 source was controlled using the Chipsoft 8.3.1 software (Advion Biosciences, Ithaca NY). 11
Three microliters of each sample were loaded into a 96-well plate and injection volume was 12 one and a half microliters. Full scan spectra were collected at the m/z 500-2,000 in positive 13 ion mode. The mass spectra of each sample were acquired in profile mode over 4 min. The 14 spectra were analyzed using XCalibur TM Software (Thermo Fisher Scientific, Waltham, MA). 15
Deconvoluted ESI spectra are presented. 16 17 Circular dichroism 18 75 μg of p53 core domain proteins were incubated with or without 2 mM MQ in 250µl 40mM 19 potassium phosphate buffer (pH 7.5) and 1 mM DTT for 1hr at 21ºC. CD measurements were 20 performed on Jasco-810 (Jasco Inc., Tokyo, Japan) with 0.01 pathlength. Denaturation curves 21 were obtained by measuring the circular dichroism spectra at 218 nm. Melting 
Immunofluorescence staining 11
Cells were plated into a 16 well chamber slide at a density of 3000 cells per well, allowed to 12 attach overnight, and treated with 25µM APR-246 or 5µM MQ/MQ-H for 16hr. Cells were 13 washed, fixed with 4% formaldehyde and permealized with 0.2% Triton X. Mouse PAb1620 14 or HO3.5 antibody were co-incubated with rabbit FL-393 antibody, all were diluted 1:200 in 2% 15 BSA for 1hr at 4˚C. Anti-rabbit Alexa 488 and anti-mouse Alexa 594 conjugates were used as 16 secondary antibody with 1:200 dilution in 2% BSA. 17 18
Flow cytometry 19
Cells were grown on 6-well plates at an initial density of 500,000 cells/well. Sixteen hours 20 later cells were transfected for 24 hr with p53 expression vectors or empty vector using 21
Lipofectamine 2000 according to the manufacturer's protocol (Life Technology, Waltham, 22 MA). The medium was then replaced with fresh medium, the cells were reseeded at a density 23 of 20,000 cells/well after 6hr culture, and treated with APR-246 on the following day. Cells 24 were collected 24 hr post-treatment, stained with Annexin V, fixed with 4% formaldehyde, 25 permealized with 90% methanol and stained with Fas, Bax and p21 antibodies. Cells were 1 analyzed on a NovoCyte Flow Cytometer (ACEA Biosciences, Solna, Sweden substitutions had little or no effect on wt (a), R273H (b) and R175H (c) core domains at 2 23 mM concentration. Higher concentrations of MQ (1, 2 or 4 mM) did not thermostabilize the 24 indicated p53 core domain proteins with C277A substitution (d). 25 The differences in the Tm values of wt, R175H and R273H p53 core domains between Table  8 1 and data presented in the main text (Results p. 5-6) are due to different batches of protein 9 and iCycler instruments for DSF. 
